Opportunities in the C5 inhibitors market include developing next-gen biosimilars and biosuperiors to improve administration frequency and expand treatment indications for diseases like aHUS, SCD, MG, ...

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into ...

Gefurulimab showed significant improvements in MG-ADL scores in the phase 3 PREVAIL study for anti-AChR antibody-positive gMG patients. The treatment was well tolerated, with a safety profile ...

Atypical hemolytic–uremic syndrome is a genetic, life-threatening, chronic disease of complement-mediated thrombotic microangiopathy. Plasma exchange or infusion may transiently maintain normal levels ...

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) today announced positive topline results from its Phase 1 single ascending dose (SAD) study in healthy participants of RLYB116, ...

4DMT acquires all world-wide rights to short-form human complement factor H (sCFH) from Aevitas Therapeutics, Inc.; technology invented at University of Pennsylvania Announces sCFH as payload for ...

The first-in-class oral factor D inhibitor danicopan (Voydeya) has been approved for the management of extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH). EVH affects ...

A research team at the Medical University of South Carolina reports in Cells that the complement system, part of the body's natural immune defenses, is a key driver of inflammatory responses that ...

Recently approved treatments for generalized myasthenia gravis (gMG), including complement and neonatal Fc receptor (FcRn) inhibitors, offer a new treatment paradigm, though challenges remain. "An ...

-- $12 million in upfront and guaranteed near-term milestone payments expected to extend cash runway into the second half of 2027 -- -- Eligible to receive up to a total of $592 million including the ...